Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chondroitin sulfate proteoglycans (CSPGs) are a family of extracellular matrix molecules composed of a core protein covalently attached to one or more chondroitin sulfate glycosaminoglycan (GAG) side chains. They are widely distributed in various tissues, including cartilage and the central nervous system, where they play structural and regulatory roles. Major subtypes include Aggrecan, Versican, Neurocan, NG2, Brevican, and Phosphacan. CSPGs are implicated in diverse processes such as cell adhesion, migration, axon guidance, and glial scar formation, making them relevant to CNS injury, neuropsychiatric disorders, and neurodegenerative diseases. Functional activities are primarily attributed to the chondroitin sulfate moieties.
Enzymatic digestion of chondroitin sulfate GAG chains to reduce inhibitory barriers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chondroitin Sulfate Proteoglycan (CSPG).